December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2009-018174-54/ Novartis Protocol ID CERL080A2423

MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic®-based regimen in the conversion from a CNI to everolimus in de novo transplant recipients of Expanded Criteria of Donor kidneys

Trial CERL080A2423 was cancelled with no patient enrollment and as such, no results will be reported.